Evidence that depletion of the sorting nexin 1 by siRNA promotes HGF-induced MET endocytosis and MET phosphorylation in a gefitinib-resistant human lung cancer cell line

International Journal of Oncology

Volumn 44, Issue 2, 2014, Pages 412-426

  Nishimura, Yukio ^a   Takiguchi, Soichi ^b   Ito, Shigeru ^c   Itoh, Kazuyuki ^d  

^a KYUSHU UNIVERSITY   (Japan)

^b NATIONAL KYUSHU CANCER CENTER   (Japan)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^d OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

Author keywords

Endocytosis; Endosomes lysosomes; Epidermal growth factor receptor; Gefitinib; Hepatocyte growth factor; MET; Non small cell lung cancer cell lines; Phosphorylated MET; Sorting nexin 1

Indexed keywords

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; ENDOCYTOSIS; ENDOSOMES; GENE SILENCING; HEPATOCYTE GROWTH FACTOR; HUMANS; LUNG NEOPLASMS; MICROSCOPY, FLUORESCENCE; PHOSPHORYLATION; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-MET; QUINAZOLINES; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SORTING NEXINS; TUMOR CELLS, CULTURED;

EID: 84894437562     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.2194     Document Type: Article

References (38)

1. Di Renzo MF, Narsimhan RP, Olivero M, Bretti S, Giordano S, Medico E, Gaglia P, Zara P and Comoglio PM: Expression of the Met/HGF receptor in normal and neoplastic human tissues. Oncogene 6: 1997-2003, 1991. (Pubitemid 21924039)
2. Comoglio PM and Boccaccio C: The HGF receptor family: Unconventional signal transducers for invasive cell growth. Genes Cells 1: 347-354, 1996. (Pubitemid 126673131)
3. Jeffers M, Rong S and Vande Woude GF: Hepatocyte growth factor/scatter factor-Met signaling in tumorigenicity and invasion/metastasis. J Mol Med 74: 505-513, 1996. (Pubitemid 26306792)
4. Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S and Comoglio PM: Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3: 347-361, 2003. (Pubitemid 38340304)
5. Kuniyasu H, Yasui W, Kitadai Y, Yokozaki H, Ito H and Tahara E: Frequent amplification of the c-met gene in scirrhous type stomach cancer. Biochem Biophys Res Commun 189: 227-232, 1992. (Pubitemid 23030031)
6. Kijima Y, Hokita S, Yoshinaka H, Itoh T, Koriyama C, Eizuru Y, Akiba S and Aikou T: Amplification and overexpression of c-met gene in Epstein-Barr virus-associated gastric carcinomas. Oncology 62: 60-65, 2002. (Pubitemid 34124227)
7. Nakazawa K, Dobashi Y, Suzuki S, Fujii H, Takeda Y and Ooi A: Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers. J Pathol 206: 356-365, 2005. (Pubitemid 40903200)
8. Miller CT, Lin L, Casper AM, Lim J, Thomas DG, Orringer MB, Chang AC, Chambers AF, Giordano TJ, Glover TW and Beer DG: Genomic amplification of MET with boundaries within fragile site FRA7G and upregulation of MET pathways in esophageal adenocarcinoma. Oncogene 25: 409-418, 2006. (Pubitemid 43117626)
9. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC and Jänne PA: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039-1043, 2007. (Pubitemid 46799492)
10. Lutterbach B, Zeng Q, Davis LJ, Hatch H, Hang G, Kohl NE, Gibbs JB and Pan BS: Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. Cancer Res 67: 2081-2088, 2007. (Pubitemid 46424226)
11. Nakamura T, Teramoto H and Ichihara A: Purification and characterization of a growth factor from rat platelets for mature parenchymal hepatocytes in primary cultures. Proc Natl Acad Sci USA 83: 6489-6493, 1986. (Pubitemid 17174760)
12. Birchmeier C and Gherardi E: Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase. Trends Cell Biol 8: 404-410, 1998. (Pubitemid 28458706)
13. Birchmeier C, Birchmeier W, Gherardi E and Vande Woude GF: Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4: 915-925, 2003. (Pubitemid 37493640)
14. Ullrich A and Schlessinger J: Signal transduction by receptors with tyrosine kinase activity. Cell 61: 203-212, 1990.
15. Rodrigues GA and Park M: Autophosphorylation modulates the kinase activity and oncogenic potential of the Met receptor tyrosine kinase. Oncogene 9: 2019-2027, 1994. (Pubitemid 24194169)
16. Ma PC, Tretiakova MS, Nallasura V, Jagadeeswaran R, Husain AN and Salgia R: Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: Implications for tumour invasion. Br J Cancer 97: 368-377, 2007. (Pubitemid 47196754)
17. Henne WM, Buchkovich NJ and Emr SD: The ESCRT pathway. Dev Cell 21: 77-91, 2011.
18. Yarden Y: The EGFR family and its ligands in human cancer signaling mechanisms and therapeutic opportunities. Eur J Cancer 37: 3-8, 2001.
19. Woodburn JR: The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 82: 241-250, 1999.
20. Baselga J and Averbuch SD: ZD1839 ('Iressa') as an anticancer agent. Drugs 60 (Suppl 1): S33-S42, 2000.
21. Arteaga CL and Johnson DH: Tyrosine kinase inhibitors-ZD1839 (Iressa). Curr Opin Oncol 13: 491-498, 2001. (Pubitemid 33027902)
22. Barker AJ, Gibson KH, Grundy W, Godfrey AA, Barlow JJ, Healy MP, Woodburn JR, Ashton SE, Curry BJ, Scarlett L, Henthorn L and Richards L: Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg Med Chem Lett 11: 1911-1914, 2001. (Pubitemid 32675316)
23. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J and Haber DA: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139, 2004. (Pubitemid 38637993)
24. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE and Meyerson M: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500, 2004. (Pubitemid 38720929)
25. Nishimura Y, Bereczky B and Ono M: The EGFR inhibitor gefitinib suppresses ligand-stimulated endocytosis of EGFR via the early/late endocytic pathway in non-small cell lung cancer cell lines. Histochem Cell Biol 127: 541-553, 2007. (Pubitemid 46632449)
26. Nishimura Y, Yoshioka K, Bereczky B and Itoh K: Evidence for efficient phosphorylation of EGFR and rapid endocytosis of phosphorylated EGFR via the early/late endocytic pathway in a gefitinib-sensitive non-small cell lung cancer cell line. Mol Cancer 7: 1-13, 2008.
27. Nishimura Y, Yoshioka K, Takiguchi S, Bereczky B, Nakabeppu Y and Itoh K: A role for SNX1 in the regulation of EGF-dependent phosphorylated EGFR endocytosis via the early/late endocytic pathway in a gefitinib-sensitive human lung cancer cells. Curr Signal Transduct Ther 6: 383-395, 2011.
28. Nishimura Y, Takiguchi S, Yoshioka K, Nakabeppu Y and Itoh K: Silencing of SNX1 by siRNA stimulates the ligand-induced endocytosis of EGFR and increases EGFR phosphorylation in gefitinib-resistant human lung cancer cell lines. Int J Oncol 41: 1520-1530, 2012.
29. Worby CA and Dixon JE: Sorting out the cellular function of sorting nexins. Nat Rev Mol Cell Biol 3: 919-931, 2002. (Pubitemid 35477370)
30. Kurten RC, Cadena DL and Gill GN: Enhanced degradation of EGF receptors by a sorting nexin, SNX1. Science 272: 1008-1010, 1996. (Pubitemid 26259317)
31. Zhong Q, Lasar CS, Tronchere H, Sato T, Meerloo T, Yeo M, Songyang Z, Emr SD and Gill GN: Endosomal localization and function of sorting nexin 1. Proc Natl Acad Sci USA 99: 6767-6772, 2002. (Pubitemid 34526206)
32. Carlton J, Bujny M, Peter BJ, Oorschot VM, Rutherford A, Mellor H, Klumperman J, McMahon HT and Cullen PJ: Sorting nexin-1 mediates tubular endosome-to-TGN transport through coincidence sensing of high-curvature membranes and 3-phosphoinositides. Curr Biol 14: 1791-1800, 2004. (Pubitemid 39408768)
33. Gullapalli A, Garrett TA, Paing MM, Griffin CT, Yang Y and Trejo J: A role for sorting nexin 2 in epidermal growth factor receptor down-regulation: evidence for distinct functions of sorting nexin 1 and 2 in protein trafficking. Mol Biol Cell 15: 2143-2155, 2004. (Pubitemid 38580634)
34. Nishimura Y, Higaki M and Kato K: Identification of a precursor form of cathepsin D in microsomal lumen: characterization of enzymatic activation and proteolytic processing in vitro. Biochem Biophys Res Commun 148: 335-343, 1987.
35. Nishimura Y, Kawabata T and Kato K: Identification of latent procathepsins B and L in microsomal lumen: characterization of enzymatic activation and proteolytic processing in vitro. Arch Biochem Biophys 261: 64-71, 1988. (Pubitemid 18070781)
36. Kornfeld S and Mellman I: The biogenesis of lysosomes. Ann Rev Cell Biol 5: 483-525, 1989. (Pubitemid 19286692)
37. Sandoval IV, Arredondo JJ, Alcalde J, Gonzalez-Noriega A, Vandekerckhove J, Jimenez MA and Rico M: The residues Leu (Ile) 475-Ile (Leu) 476, contained in the extended carboxyl cytoplasmic tail, are critical for targeting of the resident lysosomal membrane protein LIMPII to lysosomes. J Biol Chem 269: 6622-6631, 1994.
38. Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, Chitale D, Motoi N, Szoke J, Broderick S, Balak M, Chang WC, Yu CJ, Gazdar A, Pass H, Rusch V, Gerald W, Huang SF, Yang PC, Miller V, Ladanyi M, Yang CH, and Pao W: MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 104: 20932-20937, 2007.